Cardiff Oncology (CRDF) vs ProMIS Neurosciences (PMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed Cardiff Oncology (CRDF) over the past year, losing 21.6% versus a loss of 51.1%. Over five years, CRDF leads with a -83.1% price change compared with -95.7% for PMN. ProMIS Neurosciences is the larger company by market cap ($86.2 million vs $84.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDF | PMN |
|---|---|---|
| Share price | $1.08 | $9.61 |
| Market cap | $84.02M | $86.18M |
| 1-day change | +1.89% | +5.03% |
| YTD return | -61.57% | +40.70% |
| 1-year return | -51.13% | -21.55% |
| 5-year return | -83.13% | -95.73% |
| EPS (TTM) | $-0.60 | $-11.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.31 | $27.40 |
| 52-week low | $0.76 | $6.27 |
| Distance from 52-week high | -67.37% | -64.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +437.96% | +343.39% |
| Average volume | 1.04M | 82.46K |
| Shares outstanding | 77.80M | 8.97M |
| Employees | 30 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMN has outperformed CRDF by 29.6 percentage points over the past year.
About Cardiff Oncology
CRDF stock →Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 30 employees
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
CRDF vs PMN FAQ
Which is bigger, Cardiff Oncology or ProMIS Neurosciences?
ProMIS Neurosciences (PMN) is larger, with a market capitalization of $86.18M compared with $84.02M for Cardiff Oncology (CRDF).
Which stock has performed better over the past year, CRDF or PMN?
PMN returned -21.55% over the past 12 months, compared with -51.13% for CRDF (price return, excluding dividends). Past performance does not predict future results.
Are Cardiff Oncology and ProMIS Neurosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiff Oncology and Biotechnology: Pharmaceutical Preparations for ProMIS Neurosciences.